Please ensure Javascript is enabled for purposes of website accessibility

Why Are So Many Marijuana Stocks Making This Key Move?

By Dan Caplinger – Updated Apr 18, 2019 at 11:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The network effect is playing out in the cannabis industry.

After seeing struggles in 2018, marijuana stocks are back in the limelight. With new legalization efforts taking place and the evolution of the recreational cannabis market in Canada starting to become clearer, interest in top stocks in the industry has returned. So far in 2019, many cannabis stocks have posted big gains that in some cases have been enough to wipe out their losses last year.

Many of the companies that have pioneered the marijuana market are in Canada, and that led them to list their shares on the Toronto Stock Exchange and other exchanges that primarily serve Canadian companies. Yet as they've grown in popularity -- and in some cases sought to make initial forays into the budding U.S. cannabis market -- many marijuana companies have decided to make their shares more readily available to U.S. investors. And interestingly, the vast majority of them are selecting the New York Stock Exchange in particular, potentially making the NYSE the place to be for pot stocks in 2019.

Building with concrete columns and three American flags on poles.

The New York Stock Exchange. Image source: Getty Images.

Has the NYSE won the pot battle?

The New York Stock Exchange and the Nasdaq Stock Market have had a rivalry for a long time. As the older player, the NYSE has a long history of serving some of the oldest and most respected companies in the U.S. By contrast, as the upstart, the Nasdaq has wooed innovative companies that are seeking to transform their industries. That distinction showed up most clearly during the tech boom of the 1990s, when the Nasdaq attracted the vast majority of companies in the technology industry.

All other things being equal, therefore, it would be reasonable to think that cannabis companies might prefer the Nasdaq over the NYSE. Marijuana companies want to emphasize their innovation and transformative potential, and they're generally looking to cater to a customer base that's in tune with the times.

During the first part of 2018, both stock exchanges did a good job of attracting high-profile cannabis companies. Cronos Group (CRON 1.95%) started the trend in February, choosing the Nasdaq for its uplisting. Tilray (TLRY) went a step further, going with the Nasdaq for a true initial public offering, skipping the step of listing on a Canadian exchange entirely. Meanwhile, Canopy Growth (CGC 4.57%) became the first pot stock to choose the NYSE.

Yet since then, the NYSE has been dominant in its ability to attract marijuana stock listings:

Why is the Nasdaq getting shut out?

Interestingly, it might be the NYSE's old-school reputation for quality that's leading so many marijuana companies to give it the nod over the Nasdaq. Just look at what the leaders of some of the companies choosing the NYSE have said lately about their moves:

  • "This strategic move aligns directly with our growth ambitions as we enter an elite peer group of respected, high-profile corporate brands listed on the NYSE." -- Aphria CEO Vic Neufeld
  • "This is a remarkable milestone for our company." -- HEXO CEO Sebastien St-Louis
  • "A listing on the NYSE is a natural step forward in our evolution as we look to broaden our investor base, increase the company's exposure, and expand our business on an international scale." -- CannTrust CEO Peter Aceto

For the cultivation companies that are seeking to bolster their reputations and establish themselves as legitimate businesses, the NYSE seems to carry more cachet.

To be fair, though, the Nasdaq has done a good job of providing a home for another subsector in the marijuana stock realm: pharmaceutical and biotech companies looking at treatments using cannabis-derived ingredients. Many of the top names in that part of the cannabis universe have gravitated toward the Nasdaq, given its reputation for listing some of the biggest biopharmaceutical and biotech companies in the world.

Keep the NYSE/Nasdaq battle in mind

As the cannabis industry evolves, you'll see more stocks make the move to U.S. exchanges. That'll be a sign of their confidence in their future success, but it'll also be another data point in whether the NYSE or the Nasdaq is winning the battle for marijuana stock listings. If the sector keeps doing as well as it's done at the beginning of 2019, that could be an important battle for the exchanges to win.

Check out the latest Aphria earnings call transcript.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool recommends CannTrust Holdings Inc and Hexo. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aphria Inc. Stock Quote
Aphria Inc.
Aurora Cannabis Inc. Stock Quote
Aurora Cannabis Inc.
$1.32 (-0.75%) $0.01
Canopy Growth Corp. Stock Quote
Canopy Growth Corp.
$3.66 (4.57%) $0.16
Cronos Group Inc. Stock Quote
Cronos Group Inc.
$3.13 (1.95%) $0.06
HEXO Corp. Stock Quote
HEXO Corp.
$0.17 (-1.35%) $0.00
CannTrust Holdings Inc Stock Quote
CannTrust Holdings Inc
$0.00 (%)
Tilray, Inc. Stock Quote
Tilray, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.